NEW YORK, August 1, 2016 /PRNewswire/ --
One of the U.S. Healthcare sector's biggest segments, the Medical Appliances and Equipment is expected to face challenges due to stiff competition and economic uncertainties. However, constant need and demand for medical instruments should continue to drive industry growth, and the segment is anticipated to grow at a CAGR rate of about 6% through 2017, according to Espicom's 2014 report. Stock-Callers.com looks closely at the following stocks today: ZELTIQ Aesthetics Inc. (NASDAQ: ZLTQ), Align Technology Inc. (NASDAQ: ALGN), Nxstage Medical Inc. (NASDAQ: NXTM), and Nevro Corp. (NYSE: NVRO). Sign up today and download for free the research reports for the stocks covered today at:
Pleasanton, California headquartered ZELTIQ Aesthetics Inc.'s stock rose 0.92%, finishing Friday's trading session at $33.95 with a total of 525,202 shares traded. The Company's shares have surged 25.09% in the last month, 13.55% over the previous three months, and 19.00% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 17.58% and 21.39%, respectively. Additionally, shares of ZELTIQ Aesthetics, which engages in developing and commercializing non-invasive products for the selective reduction of fat, have a Relative Strength Index (RSI) of 74.40.
On June 27th, 2016, ZELTIQ Aesthetics announced that following an initial pilot phase, it has initiated the global commercial launch of the CoolAdvantage™ applicator. The CoolAdvantage applicator, which features an adaptable 3-in-1 configuration and enhanced cup design, reduces treatment time by nearly 50% due to advances in the CoolSculpting® technology, which enable treatments to be safely performed at a lower temperature. ZLTQ complete research report is just a click away at:
Shares in San Jose, California headquartered Align Technology Inc. ended the session at $89.15, jumping 4.54%. The stock recorded a trading volume of 1.81 million shares, which was above its three months average volume of 694,690 shares. The Company's shares have gained 11.65% in the past month, 23.49% in the previous three months, and 35.38% since the start of this year. The stock is trading 10.66% above its 50-day moving average and 26.24% above its 200-day moving average. Moreover, shares of Align Technology, which designs, manufactures, and markets a system of clear aligner therapy, intra-oral scanners, and computer-aided design and computer-aided manufacturing services for use in dentistry, orthodontics, and dental records storage, have an RSI of 73.19.
On July 28th, 2016, Align Technology reported its financial results for Q2 ended June 30th, 2016. Clear Aligner case shipments in Q2'16 were 177,000, a 22.4% increase on y-o-y basis. The company stated that for Q2'16, revenues were $269.4 million, a 28.6% increase on y-o-y basis, and net profit was $50.1 million, or $0.62 per diluted share, up $0.23 per diluted share compared to the same period in the prior year.
On July 28th, 2016, research firm Stifel reiterated its 'Buy' rating on the Company's stock with an increase of the target price to $95 a share from $82 a share. The complimentary report on ALGN can be downloaded at:
On Friday, shares in Lawrence, Massachusetts headquartered Nxstage Medical Inc. recorded a trading volume of 799,566 shares, which was above their three months average volume of 661,800 shares. The stock saw a slight drop of 0.67%, closing the day at $22.11. The Company's shares have gained 3.61% in the last one month, 37.16% over the previous three months, and 0.91% on an YTD basis. The stock is trading 7.28% above its 50-day moving average and 21.05% above its 200-day moving average. Additionally, shares of Nxstage Medical have an RSI of 56.03.
As per notes filed with the SEC on July 19th, 2016, the Board of Directors of NxStage Medical has elected Heyward R. Donigan to serve as a director on July 15th, 2016. Sign up for your complimentary report on NXTM at:
At the close, shares in Redwood City, California headquartered Nevro Corp. recorded a trading volume of 565,451 shares, which was above their three months average volume of 514,330 shares. The stock ended the session at $82.70, climbing 1.29%. The Company's shares have gained 15.36% in the past month, 22.97% in the previous three months, and 22.50% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 11.70% and 32.43%, respectively. Furthermore, shares of Nevro have an RSI of 67.01.
On July 22nd, 2016, research firm Piper Jaffray initiated an 'Overweight' rating for the Company's stock.
On July 25th, 2016, Nevro announced that it will release its financial results for Q2 2016 after market close on August 8th, 2016. The company's management will host a conference call beginning at 1:30 p.m. Pacific Time on the same day. Download the research report for free on NVRO at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA